 | For an existing investor in a development-stage molecular diagnostics firm, conducted a detailed examination of prospective infectious-disease clinical diagnostics products based upon real-time PCR methods, their market potential, and the expected competitive environment to be faced by the company and its marketing partners. |
| Advised a young European diagnostics firm in positioning its multiplex immunoassay system for commercialization in the U.S. clinical laboratory market; reviewed product concepts in addressing infectious and autoimmune disease testing, reviewed plans for design control and manufacturing quality assurance, and provided detailed recommendations for least-burdensome courses of action to secure FDA regulatory clearance. |
| For a leading corporate R&D laboratory contemplating a spin-off startup venture, supported strategic planning by assessing opportunities for clinical genotyping applications of DNA microarrays. |
| Conducted market and technology assessments for image-based mechanical analysis and indexing of vulnerable vascular plaque for an academic institution; identified available markets, assessed potential partners and competitors, and established commercialization requirements. |
| Formulated commercialization strategies for two, unrelated development-stage companies, each of which had developed technologies for ultra-sensitive biomolecular detection applicable to chemical/biological defense, life science R&D, industrial microbiology and clinical diagnostics markets. |
| Supported feasibility development, commercialization planning and partnering initiatives of a seed-stage enterprise developing a potentially revolutionary noninvasive patient monitoring technology applicable to asthma screening/assessment and other prevalent conditions in hospital emergency departments. |
| For a producer of tools for life science research and drug development, assessed customer attitudes about sample concentration and gel electrophoresis equipment, determined unmet user needs, and established the future potential for growth of the client's two corresponding businesses. |
| An inventor sought to form a company to develop and commercialize a noninvasive technology that can predict and monitor the risk of sudden cardiac death. We were engaged to assess the opportunity presented by the technology and to develop a business plan that would support fundraising and product commercialization. |
| For a startup firm wishing to exploit a unique lab-on-a-chip technology comprised of miniaturized fluid transfer structures, automated analytical assays and integrated informatics, guided strategy development and provided executive counsel prior to the firm’s first round of venture capital financing. The client firm was later acquired by a multinational laboratory automation company, a result of sound execution of the strategy we recommended. |
| Advised a European industrial components firm in establishing the best means for its initial entry into the U.S. market for infusion pumps based upon the client's microfluidics and miniaturization technologies. |
| For a major multinational ethical pharmaceutical firm, identified opportunities in delivering disease management services to large, self-insured employers. Assessed customer attitudes, devised disease management programs, and projected their financial costs and benefits. |
| Provided consulting support for a producer of foam packaging products and specialty components to develop a strategy to improve the client's services positioning and sales revenues in medical products markets. |
| Devised a U.S. market entry strategy for a European supplier of biological safety cabinets. |
| For a raw materials supplier, advised on market entry strategies, product positioning and pricing of a new wound care substrate with antibacterial properties. |
| Explored diversification strategies in bioscience research products for a contract developer of surgical devices. |
| Reconciled differences in business performance between European and U.S. organizations, then recommended strategies to exploit the differences, for a maker of specialty papers and laboratory filtration products. |
| For a producer of dust management products and services serving the electric utility industry, supported the development of growth strategies consistent with investor requirements. |
©1998-2008 Trilogy Associates. All rights reserved.
Return to Home Page.